ClinicalTrials.gg
CompletedNCT05265286Updated May 15, 2023

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

A Phase 2 interventional study of FRSW117 in Severe Hemophilia A, sponsored by Jiangsu Gensciences lnc.. Completed at 5 sites in China. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by Jiangsu Gensciences lnc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Enrollment
67th of 80
15 · median 54
Started
2022
with 8 others
Phase 2
4 of 93
none open now
Registered
51st of 93
by date
Lead sponsor
5 of 93
Jiangsu Gensciences lnc.

Among the 93 studies in Hemophilia A with a site in China, this one is the 67th largest by enrollment of the 80 interventional ones that give a count, is one of 9 that started in 2022, is one of 4 in phase 2, and was the 51st registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

Primary objective: To assess the pharmacokinetics, Safety and immunogenicity of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection With Severe Hemophilia A(FRSW117) Secondary objectives: To assess Preliminary efficacy of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection With Severe Hemophilia A.

03

Conditions studied

  • Severe Hemophilia A

Browse trials for

Keywords

  • Pharmacokinetics;
  • Safety;
  • immunogenicity;
  • Preliminary efficacy
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The activity of the coagulation factor VIII (FVIII:C) \< 1%.
  • Patients previously treated with FVIII concentrate (s) for a minimum of 150 exposure days (EDs) prior to study entry
  • Normal or INR \< 1.3
  • Negative lupus anticoagulant

Key Exclusion Criteria:

  • Hypersensitive to any of the of the test materials (e.g. allergic to murine or hamster origin heterologous proteins)
  • History of or anaphylaxis associated with any FVIII or II immunoglobulin administration
  • Current FVIII inhibitor-positive or history of FVIII inhibitor-positive
  • Other coagulation disorder(s) in addition to hemophilia A.• Significant hepatic or renal impairment ( and AST > 2×; serum level > 2 × upper limit of normal (ULN), Urea /BUN > 2×ULN, Cr > 176.8 µmol/L)
  • One or more tests for (HIV), Antisyphilitic spirulina (TPHA) and Virus (HCV) Antibody
  • Patients who received any anticoagulant or antiplatelet therapy within one week prior screening or need to receive an anticoagulant or antiplatelet therapy during the period of clinical trials
  • Patients having major surgery or receiving blood or bood components transfusion within 4 weeks prior screening or having planned major surgery schedule during the study
  • Patients who previously participated in the other clinical trials within one month prior screening
  • Any life-threatening disease or condition which, according to the investigator's judgment, could not benefit from the trial participation
  • Patient who is considered by the other investigators not suitable for clinical study

Other protocol-defined inclusion/exclusion Criteria May Apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Arm 1 prophylaxis treatment

    Subjects of high dose group are being received four doses of FRSW117. dosing on day1(ED1), day8(ED2), day15(ED3), day22(ED4) respectively. Subjects of low dose group are being received four doses of FRSW117. dosing on day1(ED1), day8(ED2), day15(ED3), day22(ED4) respectively. All subjects are being received PK assessment in ED1 and ED4.

    Drug: FRSW117

Interventions

  • Subjects of high dose group are being received four doses(50 IU/kg,once a week or every 7 days) of FRSW117. Subjects of low dose group (40 IU/kg,once a week or every 7 days)are being received four doses of FRSW117.

    Also known as: PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

06

What researchers measure

Primary outcomes

  1. Maximum measured concentration of FVIII:C (Cmax)

    Measured by One-Stage Clotting Assay

    Time frame: Pre-dose and post dose up to 10 days

  2. Time required for the concentration of the drug to reach half of its original value (T1/2)

    Measured by One-Stage Clotting Assay

    Time frame: Pre-dose and post dose up to 10 days

  3. Area Under the Curve to Infinity (AUC)

    Measured by One-Stage Clotting Assay

    Time frame: Pre-dose and post dose up to 10 days

  4. The measure of the efficiency of the body to remove the drug and the unit is the volume of the plasma or blood cleared of drug per unit time (CL)

    Measured by One-Stage Clotting Assay

    Time frame: Pre-dose and post dose up to 10 days

  5. Evaluation of the level of anti-PEG-rFⅧFc antibody production in participants

    Time frame: Pre-dose and post dose up to 36 days

  6. Evaluation of the level of anti-PEG antibody production in participants

    Time frame: Pre-dose and post dose up to 36 days

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE V5.0

    Adverse events related to PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein according to Common Terminology Criteria for Adverse Events (CTCAE) NCI.V5.0.

    Time frame: Pre-dose and post dose up to 36 days

  2. Development of Inhibitor

    Measured by the Nijmegen-Modified Bethesda Assay

    Time frame: Pre-dose and post dose up to 36 days

  3. score of bleeding symptoms and Vital signs

    Response to treatment with PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for bleeding episodes, using the 4-point bleeding response scale

    Time frame: Pre-dose and post dose up to 36 days

07

Study locations

5 sites
  • People'S Hospital of Zhengzhou
    Zhengzhou, Henan 450000, China
  • Affiliated Hospital of Jiangnan University
    Wuxi, Jiangsu 214100, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
  • People'S Hospital of Rizhao
    Rizhao, Shandong 276800, China
  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.
    Tianjin, Tianjin 300020, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Aug 2022, 4 months.

Of 18 phase 2 interventional studies under Hemophilia A, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2022
First posted
Mar 3, 2022
StartActual
Apr 14, 2022
Primary completionActual
Aug 21, 2022
CompletionActual
Aug 21, 2022
Last update
May 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05265286
Lead sponsor
Jiangsu Gensciences lnc.
Responsible party
Sponsor
First posted
Mar 3, 2022
Start date
Apr 14, 2022
Primary completion
Aug 21, 2022
Completion
Aug 21, 2022
Last update
May 15, 2023

Study contacts

Renchi Yang, PhD
principal investigator · Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FRSW117

Start the discussion